Chronic Obstructive Pulmonary Disease with early-stage lung cancer
Conditions
Interventions
Micorwave ablation group:Micorwave ablation
Bronchoscopic thermal vapor ablation group:Bronchoscopic thermal vapor ablation
Sponsors
Henan Provincial People's Hospita,medical
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1)Patients aged 35-80 years, regardless of gender, meeting diagnostic criteria for chronic obstructive pulmonary disease (COPD). 2)Presence of ground-glass nodules (GGNs) on chest CT with a solid-to-tumor ratio (CTR) <=0.25. 3)Nodule size <2 cm, located in the upper lobes of both lungs. 4)Pathologically confirmed primary peripheral lung cancer with preoperative staging evaluation indicating clinical stage T1a or T1b N0 M0. 5)Lesion accessibility confirmed for both transbronchial and percutaneous ablation approaches by investigator assessment. 6)Patients deemed ineligible for surgery, declining surgical intervention, or unwilling/intolerant to undergo radiotherapy/chemotherapy. 7)Written informed consent obtained with demonstrated comprehension and commitment to follow-up protocols.
Exclusion criteria
Exclusion criteria: 1)Contraindications to bronchoscopy, including: a) Myocardial infarction or unstable myocardial ischemia within 1 month prior, with left ventricular ejection fraction (EF) 1/3 of the target lung lobe/subsegment or presence of paraseptal emphysema in the target area; 5)Coexisting severe emphysema in both upper and lower contralateral lung lobes, defined as low-attenuation areas (LAAs =5-7 days pre-procedure; 9)Comorbidities/medications increasing complication risks, including: Immunological disorders, Clinically significant immunosuppressant use, Asthma history, a-1 antitrypsin deficiency; 10)Daily prednisolone intake >10 mg (or equivalent glucocorticoid dosage) during screening; 11)Prior thoracic interventions: Lung/heart transplantation,Surgical lung volume reduction,Median sternotomy,Endoscopic lung reduction (valves/coils) ,Bullectomy/lobectomy; 12)Eastern Cooperative Oncology Group (ECOG) performance status >2; 13)Participation in other clinical trials within 30 days prior to enrollment; 14)Other investigator-determined contraindications for trial participation;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Ablation Rate at 12 Months Post-Procedure; | — |
Secondary
| Measure | Time frame |
|---|---|
| CAT?mMRC;Incidence of Adverse Events;Technical Success Rate;FEV1?FVC?RV?TLC?RV/TLC?DLCO;Progression-free survival;Local Control Rate; | — |
Countries
China
Contacts
Public ContactXiaoju Zhang
Henan Provincial People's Hospita,medical
Outcome results
None listed